ArticleHuman psychopharmacology2020
A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines.
Article in Human psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 41 citations in OpenAlex.
- Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin.Molecular psychiatry · 2026Trial
- Psychedelics and Autism Therapy: A Review of Current Research and Future Directions.Current issues in molecular biology · 2026Review
- Knowledge, attitudes, and perception toward new psychoactive substances among Saudi university students: a cross-sectional study.Frontiers in psychiatry · 2026Article
- The Epidemiology of Recreational Use and Availability of DOC and DOI in the United States.Journal of psychoactive drugs · 2025Article
- Tusi use among the New York City nightclub-attending population.Addiction (Abingdon, England) · 2025Article
- Evaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT.Frontiers in psychology · 2025Article
- Development of a digital intervention for psychedelic preparation (DIPP).Scientific reports · 2024Article
- Tusi: a new ketamine concoction complicating the drug landscape.The American journal of drug and alcohol abuse · 2023Article
- Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-ACS pharmacology & translational science · 2023Article
- Article
- Rumors of Psychedelics, Psychotropics and Related Derivatives inPlants (Basel, Switzerland) · 2022Review
- Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice.ACS pharmacology & translational science · 2022Article
- The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.Psychopharmacology · 2022Article
- A narrative synthesis of research with 5-MeO-DMT.Journal of psychopharmacology (Oxford, England) · 2022Review
- Article
- Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.Journal of psychopharmacology (Oxford, England) · 2021Review
- Investigation of the Structure-Activity Relationships of Psilocybin Analogues.ACS pharmacology & translational science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe number of novel psychedelic phenethylamines and tryptamines has continued to increase, but little academic research has focused on the effects of these substances. We sought to determine and compare the subjective effects of various substances.
methodsWe conducted in-depth interviews with 39 adults (75.4% male and 87.2% White) who reported experience using psychedelic phenethylamines and/or tryptamines. Participants described the effects of compounds they have used. We examined the subjective drug effects in a qualitative descriptive manner.
resultsParticipants reported on the use of 36 compounds. The majority (64.1%) reported the use of 2C series drugs, with 2C-B use being most prevalent; 38.5% reported the use of NBOMe, and 25.6% reported the use of DOx. With regard to tryptamines, 46.2% reported use, and 4-AcO-DMT was the most prevalent drug used in this class. 2C-B was often described as being more favorable than other 2C series compounds with the effects described as being comparable with MDMA and LSD. NBOMe effects were generally described in an unfavorable manner, and the effects of DOx were often described as lasting too long (12-36 hr). The effects of 4-AcO-DMT were often described as mimicking psilocybin.
conclusionKnowing the effects of various compounds can inform education, prevention, and harm reduction efforts regarding the use of these drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.